Bausch + Lomb Announces Successful Phase 3 Trial Results for LUMIFY Preservative Free Eye Drops, Matching Original's Efficacy and Safety

Reuters

Jul 29

Bausch + Lomb Announces Successful Phase 3 Trial Results for LUMIFY Preservative Free Eye Drops, Matching Original's Efficacy and Safety

Bausch + Lomb Corporation has announced the publication of results from a phase 3 study on LUMIFY® Preservative Free Redness Reliever Eye Drops in the journal Ophthalmology and Therapy. The study evaluated the efficacy and safety of the preservative-free formulation compared to the original LUMIFY eye drops in reducing ocular redness. Conducted with 380 participants, the trial demonstrated that LUMIFY Preservative Free is statistically non-inferior to LUMIFY in reducing redness, with a similar safety profile. The results suggest LUMIFY Preservative Free as a well-tolerated option for individuals with sensitivities to preservatives. Additional information is available on the LUMIFY website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch + Lomb Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250729847370) on July 29, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2555589850"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555589850\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555589850?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-29 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555589850","market":"fut","top_or_hot":-1,"title":"Bausch + Lomb Announces Successful Phase 3 Trial Results for LUMIFY Preservative Free Eye Drops, Matching Original's Efficacy and Safety","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bausch + Lomb Announces Successful Phase 3 Trial Results for LUMIFY Preservative Free Eye Drops, Matching Original's Efficacy and Safety\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bausch + Lomb Corporation has announced the publication of results from a phase 3 study on LUMIFY® Preservative Free Redness Reliever Eye Drops in the journal Ophthalmology and Therapy. The study evaluated the efficacy and safety of the preservative-free formulation compared to the original LUMIFY eye drops in reducing ocular redness. Conducted with 380 participants, the trial demonstrated that LUMIFY Preservative Free is statistically non-inferior to LUMIFY in reducing redness, with a similar safety profile. The results suggest LUMIFY Preservative Free as a well-tolerated option for individuals with sensitivities to preservatives. Additional information is available on the LUMIFY website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch + Lomb Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250729847370) on July 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bausch + Lomb Announces Successful Phase 3 Trial Results for LUMIFY Preservative Free Eye Drops, Matching Original's Efficacy and Safety</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBausch + Lomb Announces Successful Phase 3 Trial Results for LUMIFY Preservative Free Eye Drops, Matching Original's Efficacy and Safety\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-29 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bausch + Lomb Announces Successful Phase 3 Trial Results for LUMIFY Preservative Free Eye Drops, Matching Original's Efficacy and Safety\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bausch + Lomb Corporation has announced the publication of results from a phase 3 study on LUMIFY® Preservative Free Redness Reliever Eye Drops in the journal Ophthalmology and Therapy. The study evaluated the efficacy and safety of the preservative-free formulation compared to the original LUMIFY eye drops in reducing ocular redness. Conducted with 380 participants, the trial demonstrated that LUMIFY Preservative Free is statistically non-inferior to LUMIFY in reducing redness, with a similar safety profile. The results suggest LUMIFY Preservative Free as a well-tolerated option for individuals with sensitivities to preservatives. Additional information is available on the LUMIFY website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch + Lomb Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250729847370) on July 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4198","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nNDL2MnMyr:1","article_id":"2555589850","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555589850","pubTimestamp":1753786864,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Bausch + Lomb Announces Successful Phase 3 Trial Results for LUMIFY Preservative Free Eye Drops, Matching Original's Efficacy and Safety. Bausch + Lomb Corporation has announced the publication of results from a phase 3 study on LUMIFY Preservative Free Redness Reliever Eye Drops in the journal Ophthalmology and Therapy. The study evaluated the efficacy and safety of the preservative-free formulation compared to the original LUMIFY eye drops in reducing ocular redness. Conducted with 380 participants, the trial demonstrated that LUMIFY Preservative Free is statistically non-inferior to LUMIFY in reducing redness, with a similar safety profile. The results suggest LUMIFY Preservative Free as a well-tolerated option for individuals with sensitivities to preservatives. Additional information is available on the LUMIFY website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informati","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4198":"医疗保健用品","BLCO":"博士伦"},"translate_title":"博士伦宣布LUMIFY无防腐剂滴眼液3期试验结果成功，疗效和安全性与Original相当","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLCO":0.9},"content_text":"Bausch + Lomb Announces Successful Phase 3 Trial Results for LUMIFY Preservative Free Eye Drops, Matching Original's Efficacy and Safety\n    \n\n        Bausch + Lomb Corporation has announced the publication of results from a phase 3 study on LUMIFY® Preservative Free Redness Reliever Eye Drops in the journal Ophthalmology and Therapy. The study evaluated the efficacy and safety of the preservative-free formulation compared to the original LUMIFY eye drops in reducing ocular redness. Conducted with 380 participants, the trial demonstrated that LUMIFY Preservative Free is statistically non-inferior to LUMIFY in reducing redness, with a similar safety profile. The results suggest LUMIFY Preservative Free as a well-tolerated option for individuals with sensitivities to preservatives. Additional information is available on the LUMIFY website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch + Lomb Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250729847370) on July 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}